Considering that eribulin may not have cross resistance with paclitaxel, as in breast cancer [18], we selected eribulin as a combination partner with a PI3K inhibitor in paclitaxel-resistant, PI3K pathway-activated endometrial cancer. Here, PIK3CG is linked to breast cancer.